Côte d’Ivoire

The Accelerating Patient Access to Optimal Antiretrovirals and Relevant Health Products via a sub-agreement with CHAI (Project Optimal) is a follow-up to the Unitaid-funded SPAAN Project (August 2019 – July 2020). SPAAN streamlined and accelerated the introduction of new, child-friendly ARV formulations by focusing on plans for solid formulations of LPV/r and the DTG 50 mg tablet, as well as future plans to introduce DTG dispersible formulations. Building on the success of that project, Project Optimal aims to (1) streamline and accelerate the transition to WHO-recommended optimal pediatric ARV formulations, focusing on DTG 10mg dispersible tablets and LPV/r solid formulation’s, (2) strengthen information, supply chain, service delivery, and pharmacovigilance systems for pediatric ARVs, and (3) strengthen differentiated service delivery models of care for children, focusing on multi-month dispensing (MMD) and facility-based, family-centered models that include children < 5 years of age.

Funded by CHAI

With funding from ELMA Foundation, EGPAF is working in CDI to scale up opportunities for catalytic improvements in pediatric and adolescent HIV testing, treatment, and service delivery.

Unitaid is funding the CaP TB project, which aims to improve TB screening in children, and accelerate access to TB diagnosis and new child-friendly treatments for both active and latent TB - a disease which affects one million children. This project, launched in 2017, will bring new child-friendly TB drug formulations and improved diagnostic technology to 10 countries.

The SPAAN project will streamline and accelerate the introduction of new, child-friendly HIV treatment formulations. This project will focus on implementation of current plans for solid formulations of Lopinavir/Ritonavir and the Dolutegravir (DTG) 50mg tablet, as well as future plans to introduce DTG dispersible formulations. The project supported 47 health facilities as project sites and reached 5,060 HIV-positive children with new child-friendly ARV formulations.

The goal of this Global Fund-funded program was to reduce the prevalence, sickness, and death caused by HIV and AIDS in Côte d’Ivoire by strengthening the capabilities related to prevention, HIV care and treatment, and community mobilization and awareness.

Project HEART was launched in 2004 in Côte d’Ivoire, South Africa, Tanzania, and Zambia, and in 2006 in Mozambique. This eight-year project, funded through the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) and the U.S. Centers for Disease Control and Prevention (CDC), saw dramatic results. In 2010, one out of every 10 PEPFAR-supported ART patients in sub-Saharan Africa received their treatment through Project HEART.

With funding from the United States Agency for International Development (USAID) and the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), EGPAF implemented the eight-year Call to Action (CTA) project in 12 countries, including Côte d’Ivoire (from 2005 through 2007).

Through CDC funding, EGPAF will leverage lessons learned from the Namibia Extension for Community Health care and Outcomes (Project ECHO) pilot in Côte d’Ivoire.

Funded by CDC, Project Keneya Dougou aims to strengthen the technical and organizational capacity of CBOs and government-run social centers to effectively manage HIV prevention.

The CDC-funded Project Djasso allows EGPAF-Côte d’Ivoire to support facilities and strengthen systems, including training health care workers in the provision of high-quality HIV prevention, care, and treatment services.